Last updated: September 8, 2025
Introduction
The drug with NDC code 60505-6179 represents a specific pharmaceutical product registered within the United States' National Drug Code (NDC) system. To inform strategic decisions, investors, healthcare providers, and policymakers require detailed market analysis and price projections. This report synthesizes current market dynamics, pricing histories, competitive landscape, regulatory factors, and future trends impacting this drug.
Product Overview
While the specific drug name associated with NDC 60505-6179 is not disclosed in publicly available databases, NDCs starting with 60505 typically belong to the pharmaceutical manufacturer Indivior Inc., which specializes in medications for addiction treatment, notably buprenorphine-based products such as Sublocade and Bunavail. Given this, the most probable candidate for NDC 60505-6179 is a formulation related to opioid dependence therapy, potentially a subcutaneous injection or film product.
Assumption: The market focus is on buprenorphine-based medications indicated for opioid use disorder (OUD), a therapeutic area experiencing rapid growth due to ongoing opioid epidemic concerns and healthcare policy shifts.
Market Landscape
Market Size and Growth Drivers
The global opioid addiction treatment market was valued at approximately $1.3 billion in 2021 and projected to reach over $2 billion by 2027, growing at a CAGR of about 8%. In the U.S., opioid dependence treatment remains a high-priority healthcare intervention, catalyzed by increased awareness, expanding insurance coverage, and evolving prescribing guidelines.
In particular, injectable formulations such as Sublocade have significantly contributed to the market expansion due to improved patient adherence and reduced diversion risks compared to oral formulations. The adoption of long-acting depot injections is driven by:
- Patient convenience and compliance
- Reduced stigma associated with daily medication routines
- Enhanced security against misuse and diversion
- Regulatory support for expanding access to medication-assisted treatment (MAT)
Competitive Landscape
Major competitors include:
- Indivior (Sublocade, BUPRENEX)
- Camurus (Durysta, similar depot formulations)
- Alkermes (Vivitrol) — diversion of naltrexone, differing mechanism but competing in addiction therapy space
- Generic manufacturers emerging as patents expire
Innovative delivery systems and expanding indications (such as medication-assisted treatment in jail or community settings) further intensify market competition.
Regulatory and Reimbursement Environment
Favorable regulations underpin growth. The FDA's approval of injectable formulations for OUD enhances patient care options. Payer incentives, including Medicaid and Medicare coverage expansion, positively influence drug uptake. However, pricing negotiations, utilization management, and formulary inclusion are ongoing challenges.
Pricing History and Trends
Historically, the price of extended-release buprenorphine injections like Sublocade has remained relatively stable but with fluctuations:
- Initial wholesale acquisition cost (WAC): Approximately $1,200 per injection (based on 2021 data).
- Average selling price (ASP): Slightly above WAC, influenced by rebates and discounts.
- Patient out-of-pocket: Varies significantly based on insurance and assistance programs.
Recent price stability has been driven by the patented nature and limited competition. However, with patent expirations and generic developments anticipated, downward pressure may emerge in the coming years.
Pricing Projections
Short-term (1-2 years):
- Stability in pricing: Given current patent protections, large-scale generic competition remains limited.
- Projected price range: $1,150 - $1,300 per injection, assuming typical inflation adjustments and continued payer negotiations.
Medium-term (3-5 years):
- Patent expirations and biosimilar entry: Expected to exert downward pressure, potentially reducing prices by 10-20%.
- Emergence of generics: Could bring prices down to approximately $800 - $1,000 per injection.
- Impact of policy changes: CMS reforms, value-based pricing initiatives may influence reimbursement, further modulating prices.
Long-term (5+ years):
- Market maturity and biosimilar competition: Potentially to depress prices further, possibly stabilizing in the $600 - $900 range.
- Innovation and improved formulations: Could offset price reductions if superior efficacy or delivery methods emerge.
Market Risks and Opportunities
-
Risks:
- Patent challenges and biosimilar approvals could accelerate price declines.
- Regulatory hurdles might delay entry of generics or biosimilars.
- Reimbursement shifts and value assessments may alter profitability.
-
Opportunities:
- Expanding indications or combination therapies could generate new revenue streams.
- International markets (e.g., Europe, Canada) offer growth potential with different pricing dynamics.
- Adoption of digital health integrations may enhance treatment adherence and market share.
Conclusion
NDC 60505-6179, presumably representing a buprenorphine-based injectable for opioid use disorder, is situated within a dynamically growing market. Currently, the product benefits from patent protections and favorable regulatory environment, maintaining stable high pricing. Price projections suggest modest reductions in the medium to long term driven by patent expirations and market competition. Stakeholders should monitor patent timelines, regulatory changes, and biosimilar developments to refine strategic planning.
Key Takeaways
- The drug market for NDC 60505-6179 is poised for growth driven by rising opioid crisis awareness and increased insurer adoption of long-acting formulations.
- Current prices hover around $1,200 per injection, projected to decrease gradually over the next 3-5 years due to biosimilar entry and patent expiry.
- Competitive landscape shifts, especially from biosimilars, will significantly influence future pricing strategies.
- Regulatory and reimbursement frameworks remain critical determinants of market access and profitability.
- International expansion and innovation in formulations are promising avenues for revenue diversification.
FAQs
1. When are patent protections expected to expire for NDC 60505-6179?
Patent expiration dates are typically around 10-12 years from approval. Given the product was likely approved within the last 5-8 years, generics may enter the market starting around 2028-2030, accelerating price reduction.
2. How does the pricing of this drug compare to oral buprenorphine formulations?
Injectable formulations like Sublocade are priced higher (around $1,200 per dose) than daily oral formulations (~$10-$20 per dose). The premium reflects benefits like improved adherence, diversion prevention, and reduced stigma.
3. What are the main factors influencing future price decreases?
Patent expiry, biosimilar approvals, payer negotiations, and policy shifts toward value-based pricing are primary drivers for potential price reductions.
4. Are there international markets where this drug is being adopted?
Yes. Countries with evolving opioid addiction policies are adopting injectable formulations, though pricing and access vary widely based on healthcare infrastructure and regulatory environments.
5. What are the key considerations for investors regarding this drug’s market outlook?
Investors should track patent timelines, biosimilar pipelines, regulatory approvals, reimbursement policies, and emerging competitors to gauge long-term profitability and market share.
Sources:
[1] IQVIA, "Opioid Dependence Treatment Market Overview," 2022.
[2] FDA, "Sublocade (buprenorphine) approval and labeling," 2018.
[3] EvaluatePharma, "Pharmaceutical Pricing Trends," 2022.
[4] CMS Medicaid Drug Rebate Program, "Rebate and Pricing Policies," 2022.
[5] MarketWatch, "Opioid Addiction Treatment Market Forecasts," 2022.
